VERRICA PHARMACEUTICALS INC

Verrica Pharmaceuticals reports a Q2 2026 revenue surge to $5.9 M, driven by YCANTH sales, and announces a $27.5 M credit line to extend its cash runway to 2028.

Verrica Pharmaceuticals, a clinical‑stage dermatology firm, is developing innovative treatments for skin diseases like molluscum contagiosum, navigating market volatility while pursuing breakthrough therapies.

Verrica Pharmaceuticals (VRCA) sees fresh institutional backing as insider buying by John Kirby and Caligan Partners LP fuels optimism for its dermatology pipeline and potential Phase 2 acceleration.

Verrica Pharmaceuticals Inc’s stock has experienced significant volatility, with a 52-week high of $54.1 and a current price of $6.7, due to the company’s struggles with profitability and financial health.